Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2016 - 2025)

Ocular Therapeutix has reported Depreciation & Amortization (CF) over the past 13 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $1.2 million for Q4 2025, up 31.13% from a year ago — trailing twelve months through Dec 2025 was $4.3 million (up 14.32% YoY), and the annual figure for FY2025 was $4.3 million, up 14.18%.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.2 million at Ocular Therapeutix, up from $1.1 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for OCUL hit a ceiling of $1.2 million in Q4 2025 and a floor of $483000.0 in Q1 2023.
  • Median Depreciation & Amortization (CF) over the past 5 years was $771000.0 (2023), compared with a mean of $781250.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): decreased 14.54% in 2021 and later skyrocketed 95.11% in 2023.
  • Ocular Therapeutix's Depreciation & Amortization (CF) stood at $570000.0 in 2021, then decreased by 13.86% to $491000.0 in 2022, then surged by 95.11% to $958000.0 in 2023, then dropped by 0.73% to $951000.0 in 2024, then soared by 31.13% to $1.2 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $1.2 million (Q4 2025), $1.1 million (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.